Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans.

Journal of hepatology - 1 Mar 2012

Pihlajamäki Jussi, Kuulasmaa Tiina, Kaminska Dorota, Simonen Marko, Kärjä Vesa, Grönlund Sari, Käkelä Pirjo, Pääkkönen Matti, Kainulainen Sakari, Punnonen Kari, Kuusisto Johanna, Gylling Helena, Laakso Markku

Abstract excerpt

BACKGROUND & AIMS: Mechanisms leading to non-alcoholic steatohepatitis (NASH) have remained unclear, and non-invasive diagnosis of NASH is challenging. In this study, we investigated the benefits of measuring serum interleukin 1 receptor antagonist (IL-1RA) levels. METHODS: Liver biopsies from 119 morbidly obese individuals (47.5 ± 9.0 years, BMI 44.9 ± 5.9 kg/m(2)) were used for histological and gene expression...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine Transaminase
Share to Biopsy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fatty Liver

Share to Insulin Resistance

Share to Interleukin 1 Receptor Antagonist Protein

Share to Lipase

Share to Non-alcoholic Fatty Liver Disease

Share to Obesity, Morbid

Source

Identifiers

PMID: 22027586
DOI: 10.1016/j.jhep.2011.10.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans.PMID 22027586Read ↗

Interleukins and the risk of non-alcoholic fatty liver disease: a two-sample Mendelian randomization studySemantic proximity Read ↗

Adipocytokine expression associated with miRNA regulation and diagnosis of NASH in obese patients with NAFLDSemantic proximity Read ↗

The role of C5aR1-mediated hepatic macrophage efferocytosis in NASHSemantic proximity Read ↗

The levels of IL1RN is a factor influencing the onset of rheumatoid arthritis in non-alcoholic fatty liver disease.Semantic proximity Read ↗

Differential expression of miRNAs in the visceral adipose tissue of patients with non‐alcoholic fatty liver diseaseSemantic proximity Read ↗

Hepatocyte-specific IL11 cis-signaling drives lipotoxicity and underlies the transition from NAFLD to NASH.Semantic proximity Read ↗

Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis c virus genotype 1.Semantic proximity Read ↗

Polymorphisms in the receptor for advanced glycation end-products (RAGE) gene and circulating RAGE levels as a susceptibility factor for non-alcoholic steatohepatitis (NASH).Semantic proximity Read ↗

Correlation of polymorphism in the interleukin-1 receptor antagonist gene intron 2 with alcoholic liver disease.Semantic proximity Read ↗

Variations in alanine aminotransferase levels within the normal range predict metabolic and androgenic phenotypes in women of reproductive age.Semantic proximity Read ↗

Agonist of RORA Attenuates Nonalcoholic Fatty Liver Progression in Mice via Up-regulation of MicroRNA 122.Semantic proximity Read ↗

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.